Outcomes of <scp>SARS‐CoV‐2</scp> Infections in Patients with Neurodegenerative Diseases in the <scp>LEOSS</scp> Cohort

Huber, Meret K.; Raichle, Claudia; Lingor, Paul; Synofzik, Matthis; Borgmann, Stefan; Erber, Johanna; Tometten, Lukas; Rimili, Wolfgang; Dolff, Sebastian; Wille, Kai; Knauß, Samuel; Piepel, Christiane; Lanznaster, Julia; Rieg, Siegbert; Praßer, Fabian; Pilgram, Lisa; Spottke, Annika; Klockgether, Thomas; Klein, Christine; Hopfner, Franziska; Höglinger, Günter U.

doi:10.1002/mds.28554

Cited by 13 publications

(15 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The 26 remaining factors were all measured during the critical phase of the COVID-19 disease. They included vital parameters ( 6), blood values (8), symptoms (8), and observations from CT scans (4) and are displayed in Table 2. It should be noted that for the vital parameters and blood values, the LEOSS database contains the worst measured value in the corresponding phase.…”

Section: Data Collection and Patientsmentioning

confidence: 99%

See 1 more Smart Citation

Specific Risk Factors for Fatal Outcome in Critically Ill COVID-19 Patients: Results from a European Multicenter Study

Meintrup

Borgmann

Seidl

et al. 2021

JCM

Self Cite

View full text Add to dashboard Cite

(1) Background: The aim of our study was to identify specific risk factors for fatal outcome in critically ill COVID-19 patients. (2) Methods: Our data set consisted of 840 patients enclosed in the LEOSS registry. Using lasso regression for variable selection, a multifactorial logistic regression model was fitted to the response variable survival. Specific risk factors and their odds ratios were derived. A nomogram was developed as a graphical representation of the model. (3) Results: 14 variables were identified as independent factors contributing to the risk of death for critically ill COVID-19 patients: age (OR 1.08, CI 1.06–1.10), cardiovascular disease (OR 1.64, CI 1.06–2.55), pulmonary disease (OR 1.87, CI 1.16–3.03), baseline Statin treatment (0.54, CI 0.33–0.87), oxygen saturation (unit = 1%, OR 0.94, CI 0.92–0.96), leukocytes (unit 1000/μL, OR 1.04, CI 1.01–1.07), lymphocytes (unit 100/μL, OR 0.96, CI 0.94–0.99), platelets (unit 100,000/μL, OR 0.70, CI 0.62–0.80), procalcitonin (unit ng/mL, OR 1.11, CI 1.05–1.18), kidney failure (OR 1.68, CI 1.05–2.70), congestive heart failure (OR 2.62, CI 1.11–6.21), severe liver failure (OR 4.93, CI 1.94–12.52), and a quick SOFA score of 3 (OR 1.78, CI 1.14–2.78). The nomogram graphically displays the importance of these 14 factors for mortality. (4) Conclusions: There are risk factors that are specific to the subpopulation of critically ill COVID-19 patients.

show abstract

Section: Data Collection and Patientsmentioning

confidence: 99%

“…Besides the search for factors generally associated with COVID-19, some authors focused on a specific comorbidity [3][4][5][6][7][8]. Others concentrate on demographic factors such as gender [9], ethnicity [10], or BMI [11].…”

Section: Introductionmentioning

confidence: 99%

Specific Risk Factors for Fatal Outcome in Critically Ill COVID-19 Patients: Results from a European Multicenter Study

Meintrup

Borgmann

Seidl

et al. 2021

JCM

Self Cite

View full text Add to dashboard Cite

show abstract

“…Older age and male sex are important risk factors for a severe course of and/or fatality after COVID-19 infection, as are diabetes, obesity, chronic obstructive pulmonary disease, dementia, or previous neurological disease ( Williamson et al 2020;Covino et al 2020;Grasselli et al 2020;Zhou et al 2020;Bonanad et al 2020;Ko et al 2021). Pulmonary disease, obesity, and hypertension have also been specifically identified as risk factors for a severe COVID-19 disease course in PD patients (Chambergo-Michilot et al 2021;Fasano et al 2020c;Huber et al 2021). Although the risk of a complicated COVID-19 disease course is increased for people with older age and associated arterial hypertension, this risk is even higher in PD patients, especially with longer disease duration, than in non-PD patients (Fasano et al 2020b, c;Orlando et al 2021;Chambergo-Michilot et al 2021).…”

Section: Patients With Pd Are At An Increased Risk For a Complicated ...mentioning

confidence: 99%

Best practice approaches to outpatient management of people living with Parkinson’s disease during the COVID-19 pandemic

et al. 2022

Self Cite

View full text Add to dashboard Cite

The prevalence of Parkinson’s disease (PD) is rising, rendering it one of the most common neurodegenerative diseases. Treatment and monitoring of patients require regular specialized in- and outpatient care. Patients with PD are more likely to have a complicated disease course if they become infected with severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2). Regular in-hospital appointments place these patients at risk of exposure to SARS-CoV-2 due to travel and contact with other patients and staff. However, guidelines for the management of outpatients with PD during times of increased risk of infection are currently lacking. These are urgently needed to conduct risk–benefit evaluations to recommend the best medical treatment. This article discusses best practice approaches based on the current literature, as suggested by the multidisciplinary Network of University Medicine (NUM) in Germany. These include measures such as mask-wearing, hand hygiene, social distancing measures, and appropriate testing strategies in outpatient settings, which can minimize the risk of exposure. Furthermore, the urgency of appointments should be considered. Visits of low urgency may be conducted by general practitioners or via telemedicine consultations, whereas in-person presentation is required in case of moderate and high urgency visits. Classification of urgency should be carried out by skilled medical staff, and telemedicine (telephone or video consultations) may be a useful tool in this situation. The currently approved vaccines against SARS-CoV-2 are safe and effective for patients with PD and play a key role in minimizing infection risk for patients with PD.

show abstract

“…A detailed review by Fearon et al summed up that COVID-19 mortality is probably not increased in PD patients who tended to experience less dyspnea during the infection, were completely asymptomatic more often and less likely to require hospitalization [ 141 , 160 , 165 , 166 , 167 ]. The duration of ICU stays/hospitalization and ventilation did also not differ in PD and non-PD COVID-19 patients in a large analysis of German inpatients [ 165 ]. An Italian study compared COVID-19 patients with PD to COVID-19 patients without PD and found no difference in mortality (5.7% of PD COVID-19 patients died vs. 7.6% of non-PD COVID-19 patients) [ 160 ].…”

Section: Chaptermentioning

confidence: 99%

Can SARS-CoV-2 Infection Lead to Neurodegeneration and Parkinson’s Disease?

et al. 2021

Self Cite

View full text Add to dashboard Cite

The SARS-CoV-2 pandemic has affected the daily life of the worldwide population since 2020. Links between the newly discovered viral infection and the pathogenesis of neurodegenerative diseases have been investigated in different studies. This review aims to summarize the literature concerning COVID-19 and Parkinson’s disease (PD) to give an overview on the interface between viral infection and neurodegeneration with regard to this current topic. We will highlight SARS-CoV-2 neurotropism, neuropathology and the suspected pathophysiological links between the infection and neurodegeneration as well as the psychosocial impact of the pandemic on patients with PD. Some evidence discussed in this review suggests that the SARS-CoV-2 pandemic might be followed by a higher incidence of neurodegenerative diseases in the future. However, the data generated so far are not sufficient to confirm that COVID-19 can trigger or accelerate neurodegenerative diseases.

show abstract

Outcomes of SARS‐CoV‐2 Infections in Patients with Neurodegenerative Diseases in the LEOSS Cohort

Cited by 13 publications

References 7 publications

Specific Risk Factors for Fatal Outcome in Critically Ill COVID-19 Patients: Results from a European Multicenter Study

Specific Risk Factors for Fatal Outcome in Critically Ill COVID-19 Patients: Results from a European Multicenter Study

Best practice approaches to outpatient management of people living with Parkinson’s disease during the COVID-19 pandemic

Can SARS-CoV-2 Infection Lead to Neurodegeneration and Parkinson’s Disease?

Contact Info

Product

Resources

About